Alpha Teknova, Inc.

Ladies and gentlemen, thank you for standing by and welcome to the TechNova second quarter 2021 financial results call. At this time, all participant lines are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one, your telephone keypad. And to read your question, please press the pound key. Please be advised that today's conference is being recorded. If you require any further assistance, please press star zero. I would now like to hand the conference over to your speaker today, Sarah Mitchell-Moore from McDougal. Thank you. Please go ahead, Madam.

Yes, thank you, Suzanne. And welcome, everyone, to Technova's second quarter 2021 earnings conference call. On today's call, Stephen Gunstream, Technova's chief executive officer, will provide business highlights and updates, followed by Matt Lowell, Technova's chief financial officer, who will review financial results. After we conclude the prepared remarks, we will be happy to take your questions. As a reminder, the forward-looking statements that we make during this call, including those regarding business goals and expectations for the financial performance of the company, are subject to risks and uncertainties that may cause actual events or results to differ. Additional information concerning these risk factors is included in the press release the company issued earlier today and are more fully described in the company's various filings with the SEC. Today's comments reflect the company's current views, which could change as a result of new information, future events, or other factors, and the company does not obligate or commit itself to update these forward-looking statements except as required by law. The company's management believes that in addition to GAAP results, non-GAAP financial measures can provide meaningful insight when evaluating the company's financial performance and the effectiveness of its business strategies. During this call, the company will therefore use non-GAAP financial measures of certain of its results. Reconciliations of GAAP to non-GAAP financial measures are included in the press release that was issued this afternoon, which is posted to Technova's website and also available on the SEC website. Non-GAAP financial measures should also be considered only as a supplement to and not a substitute for financial measures prepared in accordance with GAAP. The non-GAAP financial measures in this presentation may differ from similarly named non-GAAP financial measures used by other companies. Please also be advised that the company has made available a supplemental slide deck to accompany today's prepared remarks, which can be viewed on this current webcast and accessed on the investor relations section of TechNova's website. And with that, I'll turn the call over to Stephen.

Thank you, Sarah. Good afternoon and thank you everyone for joining us for technos first ever earnings call i'd like to extend a warm welcome to our analysts and new investors who participated in our recent initial public offering which closed in June. We have technos our leading provider of critical reagents that support the discovery development and production of drug therapies novel vaccines and molecular diagnostics. We have a strong competitive position in the marketplace and are differentiated by our ability to manufacture high quality custom reagents with short turnaround times and to scale with our customers from discovery to commercialization. This is best exemplified in cell and gene therapy where there is a significant need for custom made reagents in volumes less than 1,000 liters. Our rapid delivery of custom clinical grade bioprocessing solutions enabled our cell and gene therapy customers to reduce the time from drug discovery to clinical impact. We have the infrastructure in place today to support our near-term growth outlook and are positioning the company for long-term success by investing in capacity expansion, marketing, sales, and R&D. The strength of our existing business and the success of our recent financing efforts, including, of course, our IPO, will both support those investments in the pursuit of our growth strategy. Lastly, we have the team in place to execute on our vision. I want to thank all of our 200 plus associates whose dedication has been and will continue to be critical to our success. Moving to our business update, I am pleased to report that in the second quarter we performed well commercially and made meaningful progress on our investment priorities. Matt will provide the details of our second quarter financial results, but first I'd like to highlight some notable accomplishments. Our total Q2 revenue excluding sample transport media was $8.3 million, up 41% as compared to $5.9 million in the same period of the prior year. We completed our initial public offering, raising $99.1 million in proceeds after deducting for underwriting discounts and commissions and other offering expenses. We strengthened the company's board of directors with appointments of life science veterans Bob McNamara, Brett Robertson, and Alex Spock as independent directors. We began construction on our new state-of-the-art GMP manufacturing facility in Hollister, California, which, when operational at the end of 2022, will increase production capacity by five-fold. And finally, we established our scientific affairs team, which will drive engagement with scientists developing novel cell and gene therapies. Overall, we are encouraged by our second quarter performance and are excited with the progress we've made in executing on our strategic plan. I will now hand the call over to Matt for discussion of the financials.